Figure 7
![Figure 7](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1476-4598-11-31/MediaObjects/12943_2011_Article_1011_Fig7_HTML.jpg)
Antitumor activity of oncolytic adenovirus SG600-IL-24, IFN-α and their combination in HCCLM3 xenograft model. Tumor-bearing mice were treated with PBS, IFN-α daily for 10 days, 2 x 108 PFU of SG600-IL-24 every 2 days for 10 days, or the combination of IFN-α and SG600-IL-24 therapy for 10 days. A, Tumor was measured and volume was calculated, with the time shown from the start of treatment. Data shows mean ± SD (n = 8), though the error bar for the combined treatment group is too small to be clearly identified. B, Kaplan-Meier survival curve. The symbol * indicates a significant difference was observed as compared to the SG600-IL-24 treatment group, and † indicates a significant difference was observed as compared to the IFN-α group